OBJECTIVE:To evaluate the economic burden of chronic hepatitis B(CHB)and its complications,and to e-valuate the benefits of treatment with interferon-?.METHODS:The components of the economic burden of disease included direct medical costs and non-medical costs as well as indirect economic loss per patient-year in patients with chronic hepatitis B virus infections,including chronic hepatitis B,compensated and decompensated cirrhosis,and hepatocellular carcinoma.Net cost savings due to treatment of CHB with interferon-?were estimated using clinical data from2therapeutic schemes used in hospital.RESULTS:For the patients at different stages of hepatopathy,the direct medical cost and economic burden per year were different:9000yuan,11362yuan(CHB);13865yuan,19412yuan(compensated cirehosis);25678yuan,36979yuan(decompensated cirrhosis);26501yuan,40264yuan(liver cancer),Compared with conrentional therapy against CHB,the direct medical cost and total cost were reduced following4months treatment of interferon-?after5-year follow-up.The reduced amounts were831yuan,2038yuan per person,respectively.The surrival rate rised by2.8%.CONCLUSION:CHB infections create a heavy economic burden on the society,as well as patients and their families.We have seen the potential cost-savings due to treatment with interferon-?.

OBJECTIVE:To provide reference for rational use of antiviral drugs for hepatitis B viral (HBV) in the clinic. METHODS:The application of antiviral drugs for HBV in a hospital during 2010-2014 was analyzed statistically in respects of con-sumption sum,DDDs,serial number ratio(B/A),etc. RESULTS:Total consumption sum of antiviral drugs for HBV in a hospital increased from 5 698 200 yuan to 20 115 600 yuan during 2010-2014,and annual average rate of growth (AARG) of entecavir 76.37%. The consumption sum of ordinary interferon decreased year by year,with AARG of -20.30%. Besides DDDs of ordinary interferon declined year by year,DDDs of all antiviral drugs for HBV showed a trend of increased year by year,among which the increase of entecavir was the most obvious,being 1 366.30%from 2010 to 2014. The B/A value of lamivudine,telbivudine and or-dinary interferon were equal to or close to 1 for consecutive 5 years,and the number of patients was well synchronized with con-sumption sum. CONCLUSIONS:Nucleoside (acid) analogues has become an important method of HBV antiviral treatment,and the drugs should be selected reasonably according to the specific condition of patients in clinical treatment,in order to improve the safety,effectiveness and economy of treatment.